Pretreatment TNM staging of childhood rhabdomyosarcoma

  title={Pretreatment TNM staging of childhood rhabdomyosarcoma},
  author={Walter Lawrence and James R. Anderson and Edmund A. Gehan and Harold M. Maurer},
The Intergroup Rhabdomyosarcoma Study Group (IRSG) studies began in 1972 and initially used a clinicopathologic system to place patients into prognostic groups. Because of interest in the development of a pretreatment staging system for assessing the posttreatment outcomes of patients with this disease, potential staging elements were retrospectively evaluated in a subset of 505 patients who participated in IRS‐II, an IRSG clinical trial. 
Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Patients with a histologic diagnosis of aRMS/N1 received intensified chemotherapy with systematic locoregional treatment in the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 protocol.
Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma
A recent review of cases from the Soft Tissue Sarcoma Committee of the Children's Oncology Group suggests that anaplasia might be more common than previously reported and may impact clinical outcome.
Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second‐line chemotherapy
A retrospective multicenter analysis was conducted to analyze the efficacy of various second‐line chemotherapy regimens in this setting and concluded that salvage chemotherapy at relapse is a viable option.
Management of Rhabdomyosarcoma in Pediatric Patients.
Surgical Principles for Children/Adolescents With Newly Diagnosed Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
The current surgical therapy recommen-dations of the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG), formerly known as the Intergroup Rhabdomyosarcoma Group (IRSG), are described.
Long‐term evaluation of orbital rhabdomyosarcoma in children
Orbital rhabdomyosarcoma (ORMS) is associated with an excellent survival rate greater than 85%, and is considered to be a favourable site for this tumour. Treatment is based on combination
Role of Surgery in Rhabdomyosarcoma of the Head and Neck in Children
The goal of this research is to analyze the role of surgery in the management of pediatric parameningeal and non‐PM head and neck RMS (HNRMS).
Consensus and controversies regarding the treatment of rhabdomyosarcoma
This work assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and created algorithms incorporating evidence‐based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties.
Rhabdomyosarcoma and other pediatric temporal bone malignancies.
  • M. Gluth
  • Medicine
    Otolaryngologic clinics of North America
  • 2015


Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification‐an intergroup rhabdomyosarcoma study
There is a need to develop a single prognostically significant classification of rhabdomyosarcomas and other related tumors of children, adolescents, and young adults which would allow valid comparison of outcomes between protocols carried out anywhere in the world, and should enhance recognition of prognostic subsets.
Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II).
A retrospective assessment of the relationship of these pretreatment observations to survival experience indicates definite prognostic significance for all of the individual factors used on the International Union Against Cancer (UICC) pretreatment staging system except clinical status of regional nodes.
The Third Intergroup Rhabdomyosarcoma Study.
  • W. Crist, E. Gehan, R. Heyn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
Intensification of therapy for most patients in IRS-III, using a risk-based study design, significantly improved treatment outcome overall and was also possible to decrease therapy for selected patient subsets without compromising survival.
A clinical and pathological staging system for soft tissue sarcomas
The staging system now can be used for case evaluation for therapy determination and for intercomparison of series of patients as to incidence of different kinds of tumors, effects of treatment, and survival.
Adult Soft Tissue Sarcomas: A Pattern of Care Survey of the American College of Surgeons
Survival curves support the prognostic validity of the AJCCS system and the value of complete resection of soft tissue sarcomas and adverse prognostic factors included positive surgical margins, large tumors, retro- peritoneal or mediastinal primary sites, and the perceived need for adjuvant therapy.
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Nonparametric Estimation from Incomplete Observations
Abstract In lifetesting, medical follow-up, and other fields the observation of the time of occurrence of the event of interest (called a death) may be prevented for some of the items of the sample
An access-oriented negotiated fee schedule. The Caterpillar experience.
The goal of the CAT method of surgeon reimbursement is to gain physician support for an access-oriented, market-driven negotiated fee schedule, which is not formula-driven and depends on physician acceptance.
The intergroup rhabdomyosarcoma study‐I. A final report
The authors conclude that for the therapeutic regimens evaluated there was no therapeutic advantage to including radiation in the treatment of Clinical Group I disease, or cyclophosphamide given as a daily low‐dose oral regimen in thetreatment of clinical Group II disease or Adriamycin in the Treatment of Clinical Groups III and IV diseases.